

Springer Theses

Recognizing Outstanding Ph.D. Research

Aims and Scope

The series “Springer Theses” brings together a selection of the very best Ph.D. theses from around the world and across the physical sciences. Nominated and endorsed by two recognized specialists, each published volume has been selected for its scientific excellence and the high impact of its contents for the pertinent field of research. For greater accessibility to non-specialists, the published versions include an extended introduction, as well as a foreword by the student’s supervisor explaining the special relevance of the work for the field. As a whole, the series will provide a valuable resource both for newcomers to the research fields described, and for other scientists seeking detailed background information on special questions. Finally, it provides an accredited documentation of the valuable contributions made by today’s younger generation of scientists.

Theses are accepted into the series by invited nomination only and must fulfill all of the following criteria

- They must be written in good English.
- The topic should fall within the confines of Chemistry, Physics, Earth Sciences, Engineering and related interdisciplinary fields such as Materials, Nanoscience, Chemical Engineering, Complex Systems and Biophysics.
- The work reported in the thesis must represent a significant scientific advance.
- If the thesis includes previously published material, permission to reproduce this must be gained from the respective copyright holder.
- They must have been examined and passed during the 12 months prior to nomination.
- Each thesis should include a foreword by the supervisor outlining the significance of its content.
- The theses should have a clearly defined structure including an introduction accessible to scientists not expert in that particular field.

More information about this series at <http://www.springer.com/series/8790>

Daniel Yuan Qiang Wong

Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches

Doctoral Thesis accepted by
the National University of Singapore, Singapore

 Springer

Author

Dr. Daniel Yuan Qiang Wong
Department of Chemistry
National University of Singapore
Singapore
Singapore

Supervisor

Prof. Ang Wee Han
Department of Chemistry
National University of Singapore
Singapore
Singapore

ISSN 2190-5053

Springer Theses

ISBN 978-981-10-8593-2

<https://doi.org/10.1007/978-981-10-8594-9>

ISSN 2190-5061 (electronic)

ISBN 978-981-10-8594-9 (eBook)

Library of Congress Control Number: 2018934379

© Springer Nature Singapore Pte Ltd. 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature

The registered company is Springer Nature Singapore Pte Ltd.

The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

Supervisor's Foreword

As Daniel Wong's graduate advisor during his Ph.D., I am pleased to write this foreword for this publication in Springer Theses. Daniel joined my laboratory as my first batch of final year project undergraduate students in 2010. He was working on the synthesis of targeted platinum(IV) anticancer complexes. He subsequently received a departmental scholarship and continued on to do his Ph.D. with me. In his 5 years with me, Daniel has been a self-motivated, independent and creative scientist. He has been highly curious and always discussing new potential project ideas with me. As a scientist, Daniel is willing to dive into the 'unknown' and take calculated risks in his research direction instead of sticking with the 'tried and proven'. I have watched him grown from a trainee student under my tutelage into a proficient scientist, himself mentoring another younger generation of scientists. In recognition of his research excellence, Daniel has won the prestigious Wang Gungwu Medal (2016) for the best Ph.D. thesis in the Natural Sciences in the National University of Singapore.

Broadly, this thesis is outstanding in its effort to propose new avenues for future platinum-based drug development. Platinum-based chemotherapeutics such as cisplatin has been a workhorse of chemotherapy regimens for decades. Nonetheless, clinical interest in new platinum-based chemical entities (NCEs) has been waning in recent years. In this era of cancer genomics and immunotherapy, traditional cytotoxic chemotherapeutics have seemingly been left behind. It is in this context that this thesis attempts to offer a rethink of platinum-based agents and to suggest new directions for the future research.

The first contribution of this thesis is a proof-of-concept, deploying a targeted drug while retaining a broad spectrum of action in the form of a targeted cisplatin-based derivative (Chap. 4). Daniel demonstrated that such a strategy could be therapeutically favourable because it could circumvent multi-factorial apoptosis resistance inherent in heterogeneous tumours, a problem which plagues conventional molecularly targeted drugs.

Daniel's second contribution is the conceptualisation of combined platinum-based immuno-chemotherapeutics which combines chemotherapy with immunotherapy. Back when this idea was first floated, it seemed like a longshot that platinum agents,

long held to be immunosuppressive, could modulate the immune microenvironment in a way that could be therapeutically favourable. There was some evidence supporting this hypothesis in literature but they were scarce and not widely recognized within the community. Daniel has made pioneering efforts in exploring this idea with some early promising results, and as two orthogonal approaches. The first approach is a 'macrophage-centric' approach which looks at activating macrophages directly with platinum agents (Chap. 5), while the second approach is a 'tumour-centric' approach of triggering immunogenic cell death of cancer cells (Chap. 6).

The discoveries of this work have been published in outstanding top-tiered journals, including two papers in *Angewandte Chemie*, one of which as a VIP paper, and another paper in *Chemical Science*. This Springer Theses award has been well-deserved.

Singapore, Singapore
February 2018

Prof. Ang Wee Han

Parts of this thesis have been published in the following articles:

1. D. Y. Q. Wong*, W. W. F. Ong*, W. H. Ang, Induction of immunogenic cell death by chemotherapeutic platinum complexes, *Angew. Chem. Int. Ed.* 2015
2. D. Y. Q. Wong*, J. H. Lim*, W. H. Ang, Induction of targeted necrosis with HER2-targeted platinum(IV) anticancer prodrugs, *Chem. Sci.* 2015, 6, 3051–3056–
Published by The Royal Society of Chemistry
3. D. Y. Q. Wong*, C. H. F. Yeo*, and W. H. Ang, Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents, *Angew. Chem. Int. Ed.*, 2014, 26, 6752–6756
4. D. Y. Q. Wong, J. Y. Lau, W. H. Ang, Harnessing chemoselective imine ligation for tethering bioactive molecules to platinum(IV) prodrugs, *Dalton Trans.*, 2012, 41, 6104–6111

*** Equal contribution**

Acknowledgements

There are many who have contributed significantly towards the progress of my research in one way or another. Here, I will just like to acknowledge and thank them. First, I would like to express my unreserved appreciation towards my supervisor, Prof. Ang Wee Han. Without him, this research work would simply not have existed. Having been with the lab from its inception till now, I feel a sense of pride to be part of this competent, resource-rich and well-equipped lab. I'm grateful too, for Prof. Ang's confidence in me which has moulded me into a more self-assured researcher.

I'm also thankful for the presence of my fellow labmates. Thanks to Cheefei, for having shouldered the heavy burden of being the safety lead and also for being a great pal and the life of the lab. Thanks to Jianyu, the new safety lead, and Siewqi, the biological lead, for their sense of responsibility and their proactive efforts which have made the lab's working environment so much better for everyone. Thanks to Junxiang for constantly waiting for me to have lunch and whose work effort is commendable. Not forgetting—Mun Juinn, my lab 'BFF'. Thanks for being a great friend, whom I can confide in, and whose friendship I will always treasure. Finally, to the newcomers, Keefe, Sebastian and Marsha—I wish you all well.

It has been said that *the true credit belongs to the man in the arena, whose face is marred by dust and sweat and blood*. Thus, I cannot adequately thank and acknowledge the contributions of all my final year students enough. It is them, who have driven and achieved much of the work described here. Thanks to Lau Jiayi (Chap. 2, 2012), Charmian Yeo (Chaps. 3 and 5, 2013), Lim Jun Han (Chap. 4, 2014) and Wendy Ong (Chap. 6, 2014). Although not included in this thesis, Stephanie Loh and Valerie Chu (2015) made substantial progress on understanding macrophage activation and on immune checkpoint inhibitors respectively.

My family has been a constant unwavering pillar of support during these 4 years. Thanks to my dad for nudging me up every morning and for driving me to school. You are truly the most selfless and loving dad ever. Thanks to my mum for taking care of the household and for keeping me well-fed. No words are sufficient to express my gratitude. I thank my brother, Alex, and my sister, Jenny, for holding

the family together and supporting the family financially all these while throughout all the ups and downs. I also thank my sister-in-law, Meilin. It's amazing how she could juggle her research, become 'woman of the year' and still cook dinner for us! Thanks Sabbie, for your unconditional love and for everything, even though you are no longer with us. I will always miss you.

Finally, I thank my wife, Candice, for her unwavering belief and support. Without her, this Ph.D. journey would have been so much lonelier and the world would seem so much darker. Thanks for all the little words of encouragements to keep me going and for sticking with me through the tough times. I'm sorry you had to wait so long. I promise to cherish you for all the days of my life, together, forever.

feci quod potui, faciant meliora potentes

I have done what I could, let whoever can do more, do so.

Declaration

I hereby declare that this thesis is my original work and it has been written by me in its entirety, under the supervision of Dr. Ang Wee Han, Chemistry Department, National University of Singapore, between 8th Aug 2011 and 30th June 2015.

I have duly acknowledged all the sources of information which have been used in the thesis.

This thesis has also not been submitted for any degree in any university previously.

Contents

1 Introduction	1
1.1 Overview	1
1.2 Cellular Uptake and Molecular Mechanism of Action	3
1.3 Limitations	5
1.4 The Platinum(IV) Prodrug Strategy	8
1.5 Immuno-modulation by Platinum-Based Agents	18
1.6 Outline of Thesis	22
References	23
2 Harnessing Chemoselective Imine Ligation for Tethering Bioactive Molecules to Platinum(IV) Prodrugs	33
2.1 Introduction	33
2.2 Results and Discussion	35
2.3 Conclusion	41
2.4 Methods	42
Supplementary Information	45
References	51
3 Probing the Platinum(IV) Prodrug Hypothesis. Are Platinum(IV) Complexes Really Prodrugs of Cisplatin?	55
3.1 Introduction	55
3.2 Results and Discussion	58
3.3 Conclusion	63
3.4 Experimental	63
Supplementary Information	66
References	69

4 Induction of Targeted Necrosis with HER2-Targeted Platinum(IV) Anticancer Prodrugs	73
4.1 Introduction	74
4.2 Results and Discussion	75
4.3 Conclusion	82
4.4 Materials and Methods	83
Supplementary Information	87
References	100
5 Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents	103
5.1 Introduction	103
5.2 Results and Discussion	105
5.3 Conclusion	111
5.4 Methods	112
Supplementary Information	115
References	127
6 Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes	131
6.1 Introduction	131
6.2 Results and Discussion	133
6.3 Conclusion	138
6.4 Methods	139
Supplementary Information	142
References	144
7 Concluding Remarks	147
7.1 Concluding Remarks	147

List of Figures

Fig. 1.1	Platinum-based anticancer drugs which have recieved international clinical approval.	2
Fig. 1.2	The uptake and cytotoxic pathway of cisplatin. Upon entering the cell, cisplatin is hydrolyzed forming a reactive aquated species which then binds to cellular DNA leading to eventual cell death	3
Fig. 1.3	Illustration of the kink formed by the major 1,2-d(GpG) intrastrand crosslink in double stranded DNA. Reproduced from Ref. 20 with permission from The Royal Society of Chemistry [20]	4
Fig. 1.4	The platinum(IV) prodrug hypothesis: reductive elimination of platinum(IV) prodrugs occurs with the release the active platinum(II) core as well as both axial carboxylate ligands . . .	9
Fig. 1.5	JM335—an active platinum(IV) complex bearing <i>trans</i> equatorial geometry	10
Fig. 1.6	Ethacraplatin and mitaplatin are two examples of platinum(IV) complexes with active axial ligands	13
Fig. 1.7	Series of estrogen tethered platinum(IV) complexes.	14
Fig. 1.8	<i>cis</i> and <i>trans</i> isomers of light activated platinum(IV) diazido complexes.	15
Fig. 1.9	Formation of Pt-DNA adduct upon irradiation	15
Fig. 1.10	Combined immuno-chemotherapy. Cisplatin can exert both direct cytotoxicity against cancer cells as well as activating macrophages against cancer cells by upregulating TLR4 receptors on macrophages.	19
Fig. 1.11	Postulate: We hypothesize that platinum-based therapy is able to repolarize tumor-supporting M2 macrophages into cancer-killing M1 macrophages	20
Fig. 1.12	Some platinum-based agents can trigger immunogenic cell death of tumour cells by triggering ER-stress which induces the translocation of calreticulin, a potent “eat me” signal.	

	Recognition and phagocytosis of these tumour cells by dendritic cells eventually leads to the development of an acquired immune response against the tumour cells via a tumour-specific cytotoxic T cells response	20
Fig. 2.1	a Cisplatin, b satraplatin, c ethacrynic acid-conjugated platinum(IV) complex, synthesized by direct axial carboxylation with acid chloride and, d estrogen-tethered platinum(IV) complexes formed by amide coupling of an uncoordinated pendant carboxyl functional group with an amine-linker functionalized estrogen.	34
Fig. 2.2	Structures of hydrazide or aminoxy functionalized substrates, a benzhydrazide, b 4-methoxybenzhydrazide, c l-tyrosine hydrazide, d Girard's reagent D, e Girard's reagent T, f benzylhydroxylamine and g hydrazide-functionalised AMVSEF peptide.	37
Fig. 2.3	HPLC monitoring of formation Pt-benzhydrazide (top) and Pt-benzylhydroxylamine (bottom) over time in 50% DMF/aq. NaOAc (2 M, pH 4.8).	38
Fig. 2.4	Comparison between rate of imine ligation between the catalysed and uncatalysed reaction mixture; the solid and dotted line represents the fitted curves for the catalysed and uncatalysed reaction respectively to the differential rate equations for a two-step consecutive reversible reaction; Uncatalysed reaction: 0.263 mM Pt-benzaldehyde 1 , 8.71 mM benzhydrazide; Catalysed reaction: 0.263 mM Pt-benzaldehyde 1 , 8.71 mM benzhydrazide, 100 mM <i>p</i> -anisidine. Legend: Δ unreacted complex 1 , \bigcirc mono-Pt-benzhydrazide, \square bis-Pt-benzhydrazide. Filled black symbols and hollow gray symbols represent the catalysed and uncatalysed reactions, respectively	39
Fig. 2.5	RP-HPLC (254 nm) reaction monitoring of formation of Pt-AMVSEF peptide 3 over time in 20% DMF. The free hydrazide-functionalised peptide ($R_t = 13.80$ min) is not visible at 254 nm. Legend: * bis-conjugated Pt-AMVSEF 3 , \blacklozenge mono-conjugated Pt-AMVSEF and \bigcirc unreacted complex 1	41
Fig. S2.1	^1H NMR spectra of platinum(IV)-benzaldehyde complex 1 in DMSO- d_6	46
Fig. S2.2	^1H NMR spectra of complex 1 in acetone- d_6 and ESI-MS characterization.	47
Fig. S2.3	RP-HPLC assessment of purity of Pt-benzaldehyde 1 dissolved in DMF/H $_2$ O. Elution conditions for both spectra (a) and (b): 20–80% gradient elution system with aq. NH $_4$ OAc buffer (10 mM, pH 5.5) (solvent A) and MeCN (solvent B) over 15 min at 1.0 mL/min. Columns used are:	

	a Phenomenex Luna C18(2) (250 × 4.60 mm i.d), b Shimpack VP-ODS column (150 × 4.60 mm i.d)	48
Fig. S2.4	Similarities between ¹ H NMR spectrum of: a Pt-tyrosine hydrazide (2c) and b the purely organic hydrazone ligation between 4-carboxylbenzaldehyde and tyrosine hydrazide. The 3D visual illustration is generated by CORINA [46].	49
Fig. S2.5	Only slight hydrolysis of Pt-Girard's reagent T 2e was observed at pH 7.4 and 37 °C over 24 h; the λ _{max} of the spectra was at 303 nm, attributable to the hydrazone bond.	49
Fig. S2.6	Illustration of imine ligation between Pt-benzaldehyde 1 (a) and benzhydrazide to yield the mono-ligated product (b) and the bis-ligated product 2a (c)	50
Fig. 3.1	Top: <i>cisplatin</i> and <i>oxaliplatin</i> are two platinum(II) agents in clinical use today. Bottom: Satraplatin is a promising platinum(IV) anticancer prodrug under clinical trials. Complexes 1 and 2 are newly synthesized asymmetrical platinum(IV) complexes bearing a benzaldehyde moiety for facile imine ligation to any therapeutically-relevant substrate	56
Fig. 3.2	The platinum(IV) prodrug hypothesis: reductive elimination of platinum(IV) prodrugs occurs with the release the active platinum(II) core as well as both axial carboxylate ligands	56
Fig. 3.3	Top left and top right: HILIC (230 nm) and RPLC (214 nm) chromatograms respectively of the reduction of 1 by ascorbic acid. Legend: a 4-carboxylbenzaldehyde, b 1 , c dehydroascorbic acid, d ascorbic acid, e cisplatin. Bottom: Release profile of cisplatin over time. Legend: • 1 , Δ cisplatin. Note that figures show representative experiments conducted at different times using different initial concentrations of 1	59
Fig. 3.4	Top left and top right: HILIC (214 nm) and RPLC (214 nm) chromatograms respectively of the reduction of satraplatin by ascorbic acid. Legend: a satraplatin, b JM118, c ascorbic acid. Bottom: Release profile of JM118 over time. Legend: • satraplatin, Δ JM118. Note that figures show representative experiments conducted at different times using different initial concentrations of satraplatin	61
Fig. 3.5	Rate of reduction of 180 μM of 1 , 2 and satraplatin dissolved in 200 mM phosphate buffer + 137 mM NaCl in the presence of 2 mM ascorbic acid (left) or 4 mM ascorbic acid (right). Curve was fitted using graphpad prism 5	62
Fig. S3.1	Semi-preparative trace of the crude Pt(II)(NH ₃) ₂ (Cl) (carboxylbenzaldehyde). The desired product is at 16.9 min	66
Fig. S3.2	ESI-MS of the isolated Pt(II)(NH ₃) ₂ (Cl) (carboxylbenzaldehyde). m/z 411.8 [M-H] ⁻	67

- Fig. S3.3 Aquation of cisplatin to form an unidentified product. HILIC chromatograms of **a** cisplatin in PBS (containing 139 mM Cl^-) after leaving to stand and **b** cisplatin in 50 mM phosphate buffer pH 7 (without Cl^-) after 1 h, **c** the DAD-UV-vis spectrum of the peak at 15.6 min showed an absence of any chromophores, excluding the possibility that it was a reduction product containing a carboxylbenzaldehyde moiety since the latter has a characteristic absorbance at 258 nm 67
- Fig. S3.4 Left and right: HILIC (230 nm) and RPLC (214 nm) chromatograms respectively of the reduction of **2** by 2–4 mM ascorbic acid. Legend: **a** 4-carboxylbenzaldehyde, **b** **2**, **c** dehydroascorbic acid, **d** ascorbic acid, **e** cisplatin 68
- Fig. S3.5 Representative calibration curves. A fresh calibration curve was plotted per experiment. Top row: Calibration curves for cisplatin and **1** respectively at 230 and 305 nm. Bottom row: Calibration curve for JM118 and satraplatin respectively at 214 nm. 68
- Fig. 4.1 Synthesis of HER2-targeted platinum(IV)-AHNP conjugate consisting of an AHNP motif tethered to a cytotoxic platinum pharmacophore. The AHNP motif was separated with a small tripeptide spacer (GGK) and functionalized with an aminoxy(acetate) linker at the terminal lysine residue. Peptide sequence: $\text{H}_2\text{N}-\text{YC}^*\text{DGFYAC}^*\text{YMDVGGKK}$ (aminoxy)- CONH_2 (*—Linked disulfide bridge) 75
- Fig. 4.2 **a** Platinum(IV)-AHNP conjugates are much more efficiently taken up into cells. Whole cell (left) and nuclear (right) uptake after drug treatment (20 μM) for 4 h in NCI-N87 as measured by ICP-MS. Statistical analysis by unpaired Student's *t* test. **b** Platinum(IV)-AHNP conjugates selectively kill HER2 over-expressing NCI-N87 over the normal HER2 expressing A2780. A co-culture of NCI-N87 and A2780 (pre-stained with CellTracker™ Green) was drug-treated for 24 h before viability staining with PI. Statistical analysis by two-way ANOVA and Bonferroni post-tests. Means \pm s.e.m. (**p* < 0.05, ***p* < 0.01, ****p* < 0.001). 77
- Fig. 4.3 Apoptosis was evaluated by AnnexinV/PI staining of drug-treated cells after 24 h. **a** Scatter plot of treated NCI-N87 cells (15 μM drug). **b** Barchart of apoptosis-sensitive NCI-N87 (left) and apoptosis-resistant BT-474 (right) after 24 h exposure. Each bar depicts % of cells at either early-stage apoptosis, late-stage apoptosis or necrosis. Tabulated data in Table S4.1 . . . 78
- Fig. 4.4 **a** Representative overlaid microscopy images of control and treated NCI-N87 (15 μM drug for 24 h and allowed to recover

	in fresh media for a week). Differences in nuclear morphology were visualized by Hoechst 3342 staining. Untreated cells were shown at day 1 while drug-treated cells were shown at day 6. b 4a-treated NCI-N87 undergoes short-term proliferation 24 h after drug treatment but display increasing severe nuclear fragmentation over 7 d (left to right). c Clonogenic assay of NCI-N87 (left) and BT-474 (right) to assess the long-term proliferation ability of single cells drug-treated for 24 h and allowed to recover in fresh complete media. Representative image of AHNP-treated NCI-N87 colonies shown in the inset. Statistical analysis by unpaired Student's <i>t</i> test against non-treated control. Means \pm s.e.m. (***) <i>p</i> < 0.001)	79
Fig. S4.1	Measurements of cellular ROS on NCI-N87 after drug-treatment using 2',7'-dichlorofluorescein diacetate (DCFDA) which measures general oxidative stress. In some cases, cells were co-treated with butylated hydroxyanisole (BHA), an antioxidant. t-butyl hydroperoxide-treated cells was included as a positive control	87
Fig. S4.2	Intermediate-term potency of the drug conjugates as determined by MTT measurements of cellular metabolic activity after 72 h drug treatment against the NCI-N87 gastric cancer cell line. a Representative dosage-response curves. b Table of absolute IC ₅₀ (μ M). Platinum concentrations were calibrated by ICP-OES.	88
Fig. S4.3	Visual fluorescence microscopy monitoring of drug-treated NCI-N87 over time. NCI-N87 was drug-treated (15 μ M for 24 h and then allowed to recover in fresh media). Nuclear morphology were visualized by Hoechst 3342 staining. There were substantial floating dead cells in drug-treated cells in the initial 24 h drug-treatment period (not shown here). When allowed to recover after 24 h drug-treatment, 4a -treated cells undergoes a transient phase of cell-proliferation, as evidenced by a decrease in empty space at 144 h. The cells exhibited increasingly abnormal nuclear morphology over time, implying that continued long-term proliferation was unviable	89
Fig. S4.4	Cell-cycle distribution of drug-treated NCI-N87 cells over time. Drug-treated cells were permeabilized with 70% v/v ethanol and stained with propidium iodide to determine DNA content	90
Fig. S4.5	Representative photos of clonogenic assay on NCI-N87 to assess the long-term proliferation ability of drug-treated cells.	

	Single cells were seeded in a 6-well plate, drug-treated for 24 h and allowed to recover in fresh complete media for a further 15 d before counting the number of colonies formed. The number of single cells seeded per well is written on the plates	91
Fig. S4.6	a ^1H NMR of oxaliplatin(IV)-benzaldehyde scaffold 2 in DMSO- d_6 . b ESI-MS (-) characterisation of 2 : Fullscan, zoom scan (isotopic pattern) and MS/MS (top to bottom). m/z : Calculated 604.5 $[\text{M}-\text{H}]^-$, found 604.0. c RP-HPLC purity assessment of 2 dissolved in MeCN-H $_2$ O using Shimpack VP-ODS column (150 \times 5.60 mm i.d). Elution condition: 8–30% solvent B for 10 min, 30% solvent B for 8 min and finally 30–80% solvent B for 7 min	93
Fig. S4.7	a ESI-MS (-) characterisation of cisplatin(IV)-AHNP conjugate 3a : Fullscan and zoom scan (isotopic pattern) m/z : calculated 1189.1 $[\text{M}-2\text{H}]^{2-}$, found 1188.6. b HPLC chromatogram of cisplatin(IV)-AHNP conjugate 3a . The purity of the compound was assessed using Shimpack VP-ODS column (150 \times 5.60 mm i.d). Elution Condition: 8–30% solvent B for 10 min, 30% solvent B for 8 min and finally 30–80% solvent B for 7 min	96
Fig. S4.8	a ESI-MS (-) characterisation of cisplatin(IV)-dAHNP conjugate 3b : Fullscan and zoom scan (isotopic pattern) m/z : calculated 1181.1 $[\text{M}-2\text{H}]^{2-}$, found 1180.9. b HPLC chromatogram of cisplatin(IV)-dAHNP conjugate 3b . The purity of the compound was assessed using Shimpack VP-ODS column (150 \times 5.60 mm i.d). Elution Condition: 8–30% solvent B for 10 min, 30% solvent B for 8 min and finally 30–80% solvent B for 7 min	97
Fig. S4.9	a ESI-MS (-) characterisation of oxaliplatin(IV)-AHNP conjugate 4a : Fullscan and zoom scan (isotopic pattern) m/z : calculated 1237.8 $[\text{M}-2\text{H}]^{2-}$, found 1237.1. b HPLC chromatogram of oxaliplatin(IV)-AHNP conjugate 4a . The purity of the compound was assessed using Shimpack VP-ODS column (150 \times 5.60 mm i.d). Elution Condition: 8–30% solvent B for 10 min, 30% solvent B for 8 min and finally 30–80% solvent B for 7 min	98
Fig. S4.10	a ESI-MS (-) characterisation of oxaliplatin(IV)-dAHNP conjugate 4b : Fullscan and zoom scan (isotopic pattern) m/z : calculated 1229.8 $[\text{M}-2\text{H}]^{2-}$, found 1229.6. b HPLC chromatogram of oxaliplatin(IV)-dAHNP conjugate 4b . The purity of the compound was assessed using Shimpack VP-ODS column (150 \times 5.60 mm i.d). Elution Condition:	

	8–30% solvent B for 10 min, 30% solvent B for 8 min and finally 30–80% solvent B for 7 min	99
Fig. 5.1	Putative multimodal immuno-chemotherapeutic action	105
Fig. 5.2	Synthesis of <i>cis,cis,trans</i> -diamminedichlorohydroxy (4-formylbenzoate) platinum(IV) (1), <i>cis,cis,trans</i> - diamminedichloro(acetato)(4-formylbenzoate) platinum(IV) (2) and subsequent oxime ligation with various peptides	106
Fig. 5.3	Cytotoxicity IC ₅₀ of FPR1/2-targeted platinum(IV)-peptide prodrugs against FPR1/2 overexpressing cell-lines. The cell-viability of drug-treated cells was measured after 72 h incubation to plot a dose-response curve and determine the absolute IC50. Drug concentrations were calibrated to platinum measurements via ICP-OES. Means ± s.e.m. (* <i>p</i> < 0.05, *** <i>p</i> < 0.0001; Student's <i>t</i> test).	107
Fig. 5.4	Summary of drug induced cell-mediated cytotoxicity. Average cell viability (%) of U-87MG, MCF-7 and MDA-MB-231 when co-incubated with drug-treated PBMCs after 72 h. Means ± s.e.m. (*** <i>p</i> < 0.0001; Student's <i>t</i> test compared against non-activated PBMCs).	109
Fig. 5.5	Secretion of the extracellular cytokines, IFN-γ and TNF-α, after treatment of the complex 4 , free WKYMVm peptide and cisplatin for 24 h, as determined by sandwich ELISA of the cellular supernatant. Means ± s.e.m. (* <i>p</i> < 0.01, *** <i>p</i> < 0.0001; Student's <i>t</i> test)	110
Fig. S5.1	Platinum uptake studies of platinum(IV)-WKYMVm conjugate 4 in FPR1/2-expressing U-87MG cells after 4 h of incubation following pre-incubation with increasing concentrations of free competitive WKYMVm. ICP-MS readings were adjusted to pmol Pt per 10 ⁶ cells	115
Fig. S5.2	¹ H NMR spectra of complex 1 in DMSO-d ₆ with water suppression.	116
Fig. S5.3	ESI-MS (Methanol, -ve mode) characterization of complex 1 : Fullscan, MS/MS and zoomscan (top to bottom): m/z: found: 464.9 [M-H] ⁻ , calculated: 466.1.	116
Fig. S5.4	¹ H NMR spectra of complex 2 in DMSO-d ₆	117
Fig. S5.5	ESI-MS (Methanol, -ve mode) characterization of complex 2 : Fullscan, zoomscan and MS/MS (top to bottom): m/z: found: 506.82 [M-H] ⁻ , calculated: 508.2.	118
Fig. S5.6	RP-HPLC assessment of purity of Pt-Ac-benzaldehyde 2 dissolved in MeCN-H ₂ O. Elution conditions for both spectra (A) and (B): 20–80% gradient elution system with aq. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-ODS column (150 × 4.60 mm i.d)	119

Fig. S5.7	HPLC spectra of crude reaction mixture of Pt(IV)-OH-aminooxy-2-12 (3a) at 295 nm. Elution conditions: 8–45% B for 30 min followed by 90% B for the next 10 min. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) at 2.0 mL/min	119
Fig. S5.8	RP-HPLC assessment of purity of Pt(IV)-OH-aminooxy-2-12 (3a) dissolved in MeCN–H ₂ O. Elution conditions: 20–80% gradient elution system with aq. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-ODS column (150 × 4.60 mm i.d)	120
Fig. S5.9	ESI-MS (Methanol, +ve) characterization of conjugate 3a : fullscan, zoomscan and MS/MS (top to bottom): m/z: found: 915.6 [M+2H] ²⁺ and 1831.3 [M+H] ⁺ ; calculated: 1830.7.	120
Fig. S5.10	HPLC spectra of crude reaction mixture of Pt(IV)-OH-aminooxy-2-26 (3b) at 295 nm. Elution conditions: 8–45% B for 38 min, 45–80% B for 2 min followed by 90% B for the next 10 min. NH ₄ OAc buffer (20 mM, pH 7) (solvent A) and MeCN (solvent B) at 2.0 mL/min	121
Fig. S5.11	RP-HPLC assessment of purity of Pt(IV)-OH-aminooxy-2-26 (3b) dissolved in MeCN–H ₂ O. Elution conditions: 20–80% gradient elution system with aq. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-ODS column (150 × 4.60 mm i.d)	121
Fig. S5.12	ESI-MS (Methanol, +ve) characterization of conjugate 3b : fullscan, zoomscan and MS/MS (top to bottom): m/z: found: 1784.2 [M+2H] ²⁺ ; calculated: 3568.6	122
Fig. S5.13	HPLC spectra of crude reaction mixture of Pt(IV)-OH-aminooxy-WKYMVm (3c) at 295 nm. Elution conditions: 8–50% B for 45 min followed by 90% B for the next 15 min. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) at 2.0 mL/min	122
Fig. S5.14	RP-HPLC assessment of purity of Pt(IV)-OH-aminooxy-WKYMVm (3c) dissolved in MeCN–H ₂ O. Elution conditions: 20–80% gradient elution system with aq. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-ODS column (150 × 4.60 mm i.d)	123
Fig. S5.15	ESI-MS (Methanol, +ve) characterization of conjugate 3c : fullscan, zoomscan and MS/MS (top to bottom): m/z: found: 1376.9 [M+H] ⁺ ; calculated: 1375.4	123
Fig. S5.16	HPLC spectra of crude reaction mixture of Pt(IV)-OH-aminooxy-fMLFK (3d) at 295 nm. Elution conditions:	

	8–45% B for 30 min followed by 90% B for the next 10 min. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) at 2.0 mL/min	124
Fig. S5.17	RP-HPLC assessment of purity of Pt(IV)-OH-aminooxy-fMLFK (3d) dissolved in MeCN–H ₂ O. Elution conditions: 20–80% gradient elution system with aq. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-ODS column (150 × 4.60 mm i.d)	124
Fig. S5.18	ESI-MS (Methanol, –ve) characterization of conjugate 3d : zoomscan, MS/MS and fullscan (top to bottom): m/z: found: 1084.1 [M–H] [–] ; calculated: 1085.3.	125
Fig. S5.19	HPLC spectra of crude reaction mixture of Pt(IV)-Ac-aminooxy-WKYMVm (4) at 295 nm. Elution conditions: 8–50% B for 45 min followed by 90% B for the next 15 min. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) at 2.0 mL/min	125
Fig. S5.20	RP-HPLC assessment of purity of Pt(IV)-Ac-aminooxy-WKYMVm (4) dissolved in MeCN–H ₂ O. Elution conditions: 20–80% gradient elution system with aq. NH ₄ OAc buffer (10 mM, pH 7) (solvent A) and MeCN (solvent B) over 20 min at 1.0 mL/min. Column used is: Shimpack VP-ODS column (150 × 4.60 mm i.d)	126
Fig. S5.21	ESI-MS (Methanol, +ve) characterization of conjugate 4 : zoomscan, MS/MS and fullscan (top to bottom): m/z: found: 1419.1 [M–H] [–] ; calculated: 1419.4.	126
Fig. 6.1	Schematic of drug-induced immunogenic cell death (ICD)	132
Fig. 6.2	Structures of platinum agents used in this study.	133
Fig. 6.3	Phagocytosis screening: a orange-stained CT-26 cells were drug-treated (4 h) before co-incubating (2 h) with green-stained J774 macrophages and analysed by flow cytometry. The phagocytosis % was calculated from the no. of double-stained macrophages over total no. of macrophages. Inset: Fluorescence microscopy of J774 macrophages (green) engulfing CT-26 (red) as evident by mixing of the dyes. b Representative flow cytometry scatter plots showing increased phagocytosis (top right quadrant) with Pt-NHC over control. c Coating CT-26 with rCRT enabled phagocytosis while co-incubation with a CRT blocking peptide abolished phagocytosis. Means ± s.e.m. (* <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.0001; Student's <i>t</i> test)	135
Fig. 6.4	a Left: rapid patch-like surface exposure of CRT observed by confocal microscopy after drug-treatment (1 h) of CT-26 followed by surface immuno-fluorescence staining with	

	anti-CRT mAb. Right: HMGB1 release from the nuclei of CT-26 after 24 h drug-exposure (permeabilised and stained with both anti-HMGB1-Dy488 mAb and PI). b Pt-NHC enhanced ecto-CRT exposure in live cells (red shaded) compared to non-treated control (dotted line). CT26 cells were treated for 1 h (gated against PI-cells) and 4 h (gated against AnnexinV-cells) and surface-stained with an anti-CRT-PE mAb. c Left: extracellular release of ATP (left) and HMGB1 (right) of CT-26 after 24 h exposure. Means \pm s.e.m. ($*p < 0.05$, $**p < 0.01$; Student's <i>t</i> test).	136
Fig. 6.5	The anti-oxidant, trolox, quenches cellular ROS and this in turn inhibits phagocytosis. CT-26 was first pre-treated with trolox (30 min) prior to drug exposure and later co-treated with trolox and Pt-NHC (4 h). a Trolox quenched Pt-NHC induced ROS as analysed by flow cytometry. b Co-incubation of Pt-NHC with trolox significantly inhibited tumour cell phagocytosis. Means \pm s.e.m. ($*p < 0.05$, $**p < 0.01$; Student's <i>t</i> test).	137
Fig. 6.6	Cytotoxicity of Pt agents via Annexin V apoptosis assay. CT-26 cells were treated for 24 h and stained with AnnexinV-eGFP and propidium iodide. Means \pm s.e.m.	138
Fig. S6.1	Cells observed under confocal microscopy after drug treatment (4 h) and incubation with H ₂ DCFDA (ROS indicator, green) and ER-Tracker Red (red). a CT-26. b MDA-MB-231. c Colocalisation analysis after Pt-NHC treatment (1 μ M) on MDA-MB-231. White pixels indicate areas of colocalisation as determined by Costes method.	142

List of Tables

Table 1.1	Standard reduction potentials of various platinum(IV) complexes adjusted against standard hydrogen electrode reference [108]	17
Table S2.1	Representative summary of experimental data for curve fitting	50
Table 3.1	Conversion yields of 1 and 2 to cisplatin as well as satraplatin to JM118. Values are reported as mean with standard error	63
Table S3.1	Maximum solubility of 1 and 2 and satraplatin in PBS (pH 7.4). Values are reported as mean with standard error	69
Table S4.1	Tabulated data of apoptosis as evaluated by AnnexinV/PI staining of drug-treated NCI-N87 or BT-474 cells after 24 h. Each cell depicts mean % of cells at either early apoptosis, late apoptosis or necrosis	92

List of Schemes

Scheme 1.1	Oxidation of platinum(II) to platinum(IV) complexes.	11
Scheme 1.2	Schematic diagram for symmetrical dicarboxylation of platinum(IV) complexes	12
Scheme 1.3	Schematic diagram for asymmetrical carboxylation of platinum(IV) complexes	13
Scheme 2.1	Synthesis of <i>trans,cis,cis</i> -bis(4-formylbenzoate) dichlorodiammine platinum(IV) (1) and subsequent imine ligation with various substrates.	36
Scheme S4.1	Synthesis of platinum(IV)-AHNP conjugates. Reaction conditions: (I) succinimidyl 4-formylbenzoate, in DMSO, r.t. (II) acetic anhydride in DMF, r.t. (III) H ₂ O ₂ in acetic acid, r.t. (IV) 4-formyl-benzoyl chloride in acetone, pyridine, reflux. AHNP: H ₂ N-YC*DGFYAC*YMDVGGKK(aminooxy)-CONH ₂ ; dAHNP: fC*DGFYAC*yMDVGGKK(aminooxy)-CONH ₂ (*—Linked disulfide bridge).	87

Summary

Platinum-based chemotherapeutics such as cisplatin, carboplatin and oxaliplatin have been the mainstay of chemotherapy regimens for the treatment of many cancers for the last few decades. Nonetheless, clinical interest in new platinum agents appears to be waning with only a handful entering clinical trials recently. Till date, thousands of novel cytotoxic platinum complexes have been synthesized but only a few attain clinical relevance. This thesis highlights existing limitations of platinum drug design and proposes avenues for further exploration with focuses on molecularly targeted platinum chemotherapeutics with novel mechanisms of action and on combined immuno-chemotherapeutic platinum agents.

The work described in Chaps. 2 and 3 are the foundation underpinning the subsequent chapters. In Chap. 2, we developed a facile conjugation strategy via chemoselective imine ligation to tether relevant biomolecules to a platinum(IV) prodrug scaffold. This strategy was used repeatedly to synthesize the targeted platinum(IV)-peptide conjugates described in Chaps. 4 and 5. In Chap. 3, we sought to answer whether our class of asymmetrical platinum(IV) aryl scaffolds were really prodrugs of cisplatin. Validation of the platinum(IV) prodrug hypothesis is important because it is the underlying working assumption behind the targeted platinum(IV)-peptide strategies described in Chaps. 4 and 5.

The recognition that certain molecular pathways are critical to carcinogenesis and continued tumour progression and may therefore represent an Achilles' heel has triggered a revolution in cancer drug development. These molecularly targeted chemotherapeutics have made considerable progress in the clinical outcomes for many malignancies. In Chap. 4, we have developed highly potent and selective HER2-targeted platinum(IV)-AHNP prodrugs which demonstrate the feasibility of an idea of 'targeted necrosis' as a novel strategy to circumvent apoptosis resistance.

Finally, in Chaps. 5 and 6, we describe our conceptualization and realization of combined platinum-based immuno-chemotherapeutic agents which represents a significant paradigm shift from the conventional approach of directly targeting cancer. Historically, the role of the immune system towards chemotherapy outcomes has been neglected as anticancer drugs were believed to be immuno- and myelo-suppressive. Nonetheless, this has been challenged by contemporary evidence which

now suggests that many chemotherapeutics, including platinum-based agents, do stimulate the innate and/or adaptive immune system and that these ‘secret allies’ contribute tangibly towards clinical outcomes. While it has been generally accepted that platinum agents principally exert direct cytotoxic action against cancer cells via the formation of covalent platinum-DNA adducts, the recognition of platinum-induced antitumour immunomodulation is only beginning to gain traction. There have been compelling empirical evidences corroborating the immunomodulating capacity of platinum-based therapy with favourable chemotherapy outcomes. The work described here may ultimately pave the way towards superior immuno-chemotherapeutic agents and a better clinical outcome in patients.